Alimera Sciences, Inc. (ALIM) Insider Sells $17,827.62 in Stock
Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 14,494 shares of Alimera Sciences stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $17,827.62. Following the transaction, the insider now owns 98,619 shares of the company’s stock, valued at $121,301.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Alimera Sciences, Inc. (NASDAQ:ALIM) remained flat at $$1.24 on Thursday. 283,499 shares of the stock traded hands, compared to its average volume of 168,400. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. Alimera Sciences, Inc. has a 1 year low of $1.11 and a 1 year high of $1.72. The company has a market capitalization of $85.74, a P/E ratio of -4.00 and a beta of 2.15.
Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.01. analysts predict that Alimera Sciences, Inc. will post -0.27 EPS for the current year.
A number of brokerages have recently issued reports on ALIM. ValuEngine cut shares of Alimera Sciences from a “sell” rating to a “strong sell” rating in a report on Sunday, December 3rd. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Alimera Sciences in a report on Wednesday, November 22nd. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Monday, January 8th. Finally, Cowen reiterated a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Alimera Sciences has an average rating of “Hold” and an average target price of $3.38.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.